Cargando…
Homologación de vacunas contra la COVID-19: experiencia y desafíos desde su implementación en Chile
The objective of this article is to describe the experience in Chile, during 2021 and 2022, with the validation of COVID-19 vaccines administered abroad and the main obstacles during the implementation of this process. This validation is given throughout South America and, in the case of Chile, it h...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Organización Panamericana de la Salud
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10100993/ https://www.ncbi.nlm.nih.gov/pubmed/37066127 http://dx.doi.org/10.26633/RPSP.2023.62 |
_version_ | 1785025411050110976 |
---|---|
author | Santos-López, Matías Alvear-Muñoz, Francisco Arévalo-Galdames, Felipe Díaz-Navarrete, Vannia |
author_facet | Santos-López, Matías Alvear-Muñoz, Francisco Arévalo-Galdames, Felipe Díaz-Navarrete, Vannia |
author_sort | Santos-López, Matías |
collection | PubMed |
description | The objective of this article is to describe the experience in Chile, during 2021 and 2022, with the validation of COVID-19 vaccines administered abroad and the main obstacles during the implementation of this process. This validation is given throughout South America and, in the case of Chile, it has been a successful undertaking with the validation of more than two million vaccines from different countries. Validation is a systematic process involving reviews conducted by trained professionals, which helps maintain international relations with other countries and fulfill the objectives set forth by the health authority. Despite the project’s success, it has brought to light situations such as digital gaps in the population and differences in the reporting systems and types of vaccines administered in each country. The following solutions have been proposed: a public contact center for users having difficulty with the technology; more flexible requirements for validation; and the possibility of continuing with the vaccination program in Chile, always focused on protecting the population, reducing the potential risk of disease transmission, and maintaining public health. |
format | Online Article Text |
id | pubmed-10100993 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Organización Panamericana de la Salud |
record_format | MEDLINE/PubMed |
spelling | pubmed-101009932023-04-14 Homologación de vacunas contra la COVID-19: experiencia y desafíos desde su implementación en Chile Santos-López, Matías Alvear-Muñoz, Francisco Arévalo-Galdames, Felipe Díaz-Navarrete, Vannia Rev Panam Salud Publica Temas De Actualidad The objective of this article is to describe the experience in Chile, during 2021 and 2022, with the validation of COVID-19 vaccines administered abroad and the main obstacles during the implementation of this process. This validation is given throughout South America and, in the case of Chile, it has been a successful undertaking with the validation of more than two million vaccines from different countries. Validation is a systematic process involving reviews conducted by trained professionals, which helps maintain international relations with other countries and fulfill the objectives set forth by the health authority. Despite the project’s success, it has brought to light situations such as digital gaps in the population and differences in the reporting systems and types of vaccines administered in each country. The following solutions have been proposed: a public contact center for users having difficulty with the technology; more flexible requirements for validation; and the possibility of continuing with the vaccination program in Chile, always focused on protecting the population, reducing the potential risk of disease transmission, and maintaining public health. Organización Panamericana de la Salud 2023-04-14 /pmc/articles/PMC10100993/ /pubmed/37066127 http://dx.doi.org/10.26633/RPSP.2023.62 Text en https://creativecommons.org/licenses/by-nc-nd/3.0/us/Este es un artículo de acceso abierto distribuido bajo los términos de la licencia Creative Commons Attribution-NonCommercial-NoDerivs 3.0 IGO, que permite su uso, distribución y reproducción en cualquier medio, siempre que el trabajo original se cite de la manera adecuada. No se permiten modificaciones a los artículos ni su uso comercial. Al reproducir un artículo no debe haber ningún indicio de que la OPS o el artículo avalan a una organización o un producto específico. El uso del logo de la OPS no está permitido. Esta leyenda debe conservarse, junto con la URL original del artículo. Crédito del logo y texto open access: PLoS, bajo licencia Creative Commons Attribution-Share Alike 3.0 Unported. |
spellingShingle | Temas De Actualidad Santos-López, Matías Alvear-Muñoz, Francisco Arévalo-Galdames, Felipe Díaz-Navarrete, Vannia Homologación de vacunas contra la COVID-19: experiencia y desafíos desde su implementación en Chile |
title | Homologación de vacunas contra la COVID-19: experiencia y desafíos desde su implementación en Chile |
title_full | Homologación de vacunas contra la COVID-19: experiencia y desafíos desde su implementación en Chile |
title_fullStr | Homologación de vacunas contra la COVID-19: experiencia y desafíos desde su implementación en Chile |
title_full_unstemmed | Homologación de vacunas contra la COVID-19: experiencia y desafíos desde su implementación en Chile |
title_short | Homologación de vacunas contra la COVID-19: experiencia y desafíos desde su implementación en Chile |
title_sort | homologación de vacunas contra la covid-19: experiencia y desafíos desde su implementación en chile |
topic | Temas De Actualidad |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10100993/ https://www.ncbi.nlm.nih.gov/pubmed/37066127 http://dx.doi.org/10.26633/RPSP.2023.62 |
work_keys_str_mv | AT santoslopezmatias homologaciondevacunascontralacovid19experienciaydesafiosdesdesuimplementacionenchile AT alvearmunozfrancisco homologaciondevacunascontralacovid19experienciaydesafiosdesdesuimplementacionenchile AT arevalogaldamesfelipe homologaciondevacunascontralacovid19experienciaydesafiosdesdesuimplementacionenchile AT diaznavarretevannia homologaciondevacunascontralacovid19experienciaydesafiosdesdesuimplementacionenchile |